A method of treating pancreatic adenocarcinoma in an individual is disclosed. The method involves administering to the individual a therapeutically effective amount of a therapeutic agent comprising recombinant acid sphingomyelinase. In one embodiment, the therapeutic agent further includes one or more compositions selected from the group consisting of modified enzymes, fusion proteins and constitutively active mutants. In another embodiment, the therapeutic agent further includes a pharmaceutically acceptable excipient.
A method of reducing the risk of a cocaine-addicted subject relapsing in addiction is provided, the method including administering to the subject a combination of an effective amount of humanized 2E2 (h2E2) monoclonal antibody and an effective amount of a dopamine 1 receptor antagonist, such as SCH23390. Also provided are methods of reducing cocaine drug-seeking behavior, methods of reducing the neuromodulatory effect of cocaine on the brain of a subject, and a pharmaceutical composition including h2E2 monoclonal antibody, a dopamine 1 receptor antagonist, and a pharmaceutically-acceptable excipient.
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
3.
IONIZABLE LIPIDS, LIPID NANOPARTICLES FOR MRNA DELIVERY AND METHODS OF MAKING THE SAME
A composition including ionizable lipids is provided. Methods of making the ionizable lipids are also provided. Also provided are compositions forming lipid nanoparticles, wherein the composition includes the ionizable lipid, a helper lipid, a structural lipid or sterol, and a polymer-conjugated lipid. Methods of using the ionizable lipid and lipid nanoparticles are also provided.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
An apparatus for securing surgical instruments to make them accessible by a surgeon while performing an operation on a patient is provided. The apparatus includes an articulated positioning arm that has a first arm section and a second arm section. The apparatus also includes an instrument support surface extending from the second arm section of the articulated positioning arm. The apparatus further includes a mounting interface that is capable of mounting the apparatus on a surgical bed. In addition, the apparatus includes a second device support connected to the mounting interface.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
Provided herein are benzodiazepine analogs that are modified at the 7-position on the benzodiazepine ring to include a moiety selected from C2-C4 alkynyl, C3-C6 cycloalkyl, d(5)-cyclopropyl, methyl alkynyl, alkynyl-CD3, and alkynyl-CF3. Also provided are methods of use of the compounds in treating cancer, sensitizing a tumor to radiation, sensitizing a tumor to immunotherapy or chemotherapy, and treating neurological conditions associated with Type-A GABA neurotransmitter receptor function. Pharmaceutical compositions including the compounds are also provided.
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
An oral airway for use with a sedated patient is provided. The oral airway includes an elongate shaped member with a lip protector that is operatively associated with the proximal end of the elongate shaped member. The oral airway further includes a bite block that is incorporated around at least a portion of the elongate shaped member. The oral airway further includes a first channel and a second channel, both attached to the oral airway. When a scope is inserted through the oral airway, the elongate shaped member is positioned between the tongue and the scope.
A non-invasive method for the diagnosis or prognosis of endometriosis in a subject. The method includes determining the presence of one or more populations of cells in a biological sample, wherein the presence of at least one population of those one or more populations of cells in the biological sample is indicative of the presence of endometriosis in the subject, or risk of development of endometriosis in the subject, or can be correlated to prognosis of endometriosis in the subject. In various embodiments of this aspect, the population of cells include subtypes of neutrophils, macrophages, B cells, and/or T cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
C12N 5/0787 - Granulocytes, e.g. basophils, eosinophils, neutrophils or mast cells
8.
Method to Isolate Lipid Droplet Bound and Unbound Mitochondria from Liver
A method of isolating multiple mitochondria samples from liver is provided. The separation method isolates PDM from healthy, steatotic or fibrotic livers and enables the characterization of their importance in healthy vs. disease progression. Briefly, after low-speed centrifugation, the fat layer is first separated by overlaying with low sucrose buffer (MSHE) to bring the floating fat layer to the top. Next, the fat layer is collected to isolate PDM, while the supernatant is used to isolate CM.
B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University (Israel)
Mor Research Applications Ltd. (Israel)
Inventor
Gutmark-Little, Iris
Gutmark, Ephraim
Cavari, Yuval
Katoshevski, David
Abstract
The present disclosure relates to a device for treating obstructed airways. Specifically, the present disclosure relates to a device for treating the symptoms of diseases that cause persistent airflow limitation by applying air pressure oscillations and acoustic vibrations to the airways of a patient during treatment. The device may be used in a system that allows in-home treatment under remote supervision of a physician.
G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
An apparatus may comprise a controller programmed to receive information about a synchronized digital circuit comprising a plurality of Boolean gates, determine a critical path through each synchronized, combination subcircuit block of the digital circuit, identify a first set of Boolean gates among the plurality of Boolean gates positioned in the critical path, determine a hybrid equivalent gate for each Boolean gate among the first set of Boolean gates, wherein the hybrid equivalent gate has a synchronous input, a dual-rail asynchronous input, and a dual-rail output, and generate a modified digital circuit by replacing each Boolean gate among the first set of Boolean gates with a corresponding hybrid equivalent gate.
A method of performing radiofrequency lesioning on a subject is provided. The method involves introducing an outer cannula and an inner cannula into the subject percutaneously, then guiding the outer cannula and inner cannula using neuronavigation, where the inner cannula is neuronavigation-compatible and the neuronavigation uses a navigated posterior clival line (nPCL) as an anatomic reference point. Then, removing the inner cannula from the outer cannula once the outer cannula and inner cannula are placed in a position for creating a lesion in the subject. Next, inserting an electrode into the outer cannula; and passing an electrical impulse through the electrode, causing a lesion in the subject.
A system for collecting and storing solar energy is provided. The system includes one or more solar collectors, a storage medium, a storage space, a water source, one or more water pumps, and one or more solar photo voltaics. The storage medium is a phase change material (PCM) and carbon nanofibers (CNFs).
Disclosed are compositions and methods for the treatment of hydrocephalus, for example pediatric hydrocephalus. The disclosed methods employ a non-surgical tool that may be used to control CSF production rate by inducing choroid plexus-specific apoptosis. In aspects, the non-surgical tools employ an AAV vector, a promoter, a suicide gene, and a suicide gene activator to achieve targeted choroid-plexus ablation and subsequent reduction of CSF volume.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61P 25/00 - Drugs for disorders of the nervous system
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A heat pump for transporting heat with a refrigerant between an interior and an exterior of a building. The heat pump includes an indoor coil having the refrigerant flow therethrough and transfer heat with the interior of the building and an outdoor coil having the refrigerant flow therethrough and transfer heat with the exterior of the building. The heat pump includes first and second fluid paths each extending between the indoor coil and the outdoor coil and a domestic hot water tank having a cold-water supply section and a hot-water supply section. The heat pump includes a first coil disposed in the cold-water supply section of the domestic hot water tank and defining a portion of to the first fluid path and a second coil disposed in the hot-water supply section of the domestic hot water tank and defining a portion of to the second fluid path.
A cervix stabilizing device includes a handle comprising a handle body and a compartment within the handle body. A plunger includes a stopper that forms a seal against an inner wall of the compartment. An actuation assembly is operatively connected to the plunger and extends outward from a sidewall of the handle body. The actuation assembly is configured to be actuated relative to the sidewall of the handle body to retract the stopper within the compartment to increase a volume in the compartment distal of the stopper, which is used to generate a negative pressure in the compartment with the cervix stabilizing device in use. A shaft is connected to a distal end of the handle body and having a lumen extending therethrough that is in communication with the compartment such that negative pressure is increased in the lumen due to the negative pressure in the compartment.
National Yang Ming Chiao Tung University (Taiwan, Province of China)
Inventor
Diao, Jiajie
Lee, Chen-Yi
Abstract
Disclosed herein are methods for nuclear extraction and amplification using a bio-field programmable gate array. The method includes disposing a mixed droplet including one or more target nucleic acids adsorbed to magnetic beads on a microelectrode array including microelectrodes operable to form one or more actuated patterns. The method includes extracting the one or more target nucleic acids from the mixed droplet by attracting the one or more target nucleic acids using magnetic force generated by one or more coils under the microelectrodes, and switching one or more of the microelectrodes corresponding to a disposal actuated pattern to move the mixed droplet to a disposal location. The method includes merging the one or more target nucleic acids and an amplifying droplet to form a pre-amplifying droplet, heating the pre-amplifying droplet under a programmed temperature scheme to generate an amplified droplet, and visualizing the amplified droplet.
A method of reducing the risk of a sepsis-induced vascular leak, tissue edema or organ dysfunction is provided. The method involves administering an effective amount of a composition selected from the group consisting of Lipocalin 10 (SEQ ID NO: 1), a truncated Lipocalin 10 (Lcn10) protein having the amino acid sequence SEQ ID NO: 2, Lcn 10-expressing vectors for full length/truncated Lcn10, or combinations thereof to the subject, The method is also useful for reducing the risk of a heart attack-induced cardiac dysfunction, atherosclerosis, inflammatory bowel disease or diabetes-induced cardiomyopathy.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A method for predicting and assessing motion of a user in an environment. The method includes determining estimated positions of key points of the user at a first time and determining link lengths for linkages connecting the key points. The method further includes determining, for an upcoming time, predicted positions of the key points and predicted kinematics for the key points. The estimated positions, predicted positions, and kinematics are determined periodically over a time period. The method further includes classifying an activity being performed by the user over the time period and predicting a future motion path of the user for an upcoming time period. The method further includes generating a motion assessment for the user using the predicted future motion of the user and making the motion assessment available to a device or account associated with the user.
G06V 20/58 - Recognition of moving objects or obstacles, e.g. vehicles or pedestriansRecognition of traffic objects, e.g. traffic signs, traffic lights or roads
A short-chain poly(thioketal) ("PTK") polymer is provided. The polymer is produced by a method comprising reacting 2,2 dimethoxypropane (DMP) or a ketone with a dithiol monomer in the presence of an acid using a nitrogen atmosphere and stirring for a period of time from 1 to 72hrs. The ketone is selected from the group consisting of acetone, levulinic acid, pyruvic acid, sulfonyl acetone, and oxoglutaric acid.
A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
A61L 27/42 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having an inorganic matrix
C07C 323/12 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
Provided herein are compositions including a functionalized particle, optionally a liposome and a peptide tethered to the liposome, wherein the peptide is selected from a triple-helix forming peptide (THFP), a hyaluronic acid binding peptide (HBAP), or a combination thereof. Also provided herein are methods of using the functionalized particles in increasing residence time of a therapeutic agent in a target treatment area for use in drug delivery and/or treating, eradicating, or inhibiting biofilm formation.
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Certain aspects of the disclosure provide systems and methods for diagnosis and treatment of suicidal thought and behavior (STB) through reward-aversion judgment and contextual variables. Methods include generating a set of STB parameters associated with a subject, the set of STB parameters based on reward-aversion judgment variables and contextual variables and processing the set of STB parameters with a machine learning model to generate an STB prediction. The subject may then be treated based on the STB prediction.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
22.
MULTIMODE SENSOR INTEGRATION ONTO NEEDLE-BASED SENSING SYSTEMS
A wearable device for sensing at least one analyte in a biofluid is provided. The wearable device includes at least one feature configured to penetrate a skin of a use. The wearable device further includes a first sensor coupled to the feature, the first sensor configured to detect a first analyte. wherein the first sensor is in fluid communication with the feature. The wearable device further includes a second sensor configured to detect a second analyte. the second analyte being an analyte different from the first analyte. wherein the second analyte is in fluid communication with the feature.
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
23.
Recapitulating Tissue-Native Architectures in Bio-printable Hydrogels
A device for modelling physiological and pathophysiological states of the brain is provided. The device comprises a hydrogel with micropattern channels having a length, width and depth. The micropattern channels comprise cells selected from the group consisting of neurons, astrocytes, microglia, oligodendrocytes, neuronal organoids, cancer cells, cancer spheroids, brain tumoral cells and combinations thereof.
The present technology is directed to a method of treating a cancer, or multiple cancers, comprising administering to said individual one or more compounds selected from a VAV3-inhibitor such as IODVA1, followed by administration of a selective estrogen receptor modulator (SERM) and/or selective estrogen receptor degrader (SERD), to an individual in need thereof. In embodiments, the administration may be concurrently with or following IODVA1 administration.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61P 35/02 - Antineoplastic agents specific for leukemia
25.
SYSTEMS AND METHODS FOR EVALUATING AN OSCILLATORY MOTION REGULATORY DEVICE
A system and method for evaluating an oscillatory motion regulating device include a base, an oscillation mechanism, a motion sensor, and one or more processors. The base includes a plate body and an edge beam. The plate body has an upper surface, a lower surface opposite to the upper surface, and three or more edges. The edge beam is extended from one of the edges, the edge beam is configured to be mechanically attached to an oscillatory motion regulating device. The oscillation mechanism is mechanically coupled to the upper surface of the plate body. The motion sensor is operable to monitor an oscillatory motion of the base. The one or more processors are configured to cause the motion sensor to generate an oscillatory motion data of the base.
G05D 1/49 - Control of attitude, i.e. control of roll, pitch or yaw
B62D 37/06 - Stabilising vehicle bodies without controlling suspension arrangements by means of movable masses using gyroscopes
B63B 39/04 - Equipment to decrease pitch, roll, or like unwanted vessel movementsApparatus for indicating vessel attitude to decrease vessel movements by using gyroscopes directly
Described herein are CDK9 degraders that include a CDK9 binding moiety, such as AT7519 or VIP152, conjugated to a E3 ubiquitin ligase binding moiety, such as thalidomide, lenalidomide, or pomalidomide. These degraders can induce the ubiquitination of CDK9 and promote its degradation in cells. The linker covalently tethering the CDK9 binding moiety to the E3 ubiquitin ligase binding moiety can be selected to tune the solubility profile and potency of the degrader. Accordingly, the present disclosure provides compounds, compositions, kits, uses, and methods for the treatment of cancer (e.g., blood cancers such as acute myeloid leukemia or acute lymphoblastic leukemia).
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
27.
DEUTERATED BENZODIAZEPINE ANALOGS AND METHODS OF USE IN TREATING CANCER
Provided herein are benzodiazepine analogs according to the following formula: (I) wherein: R1 is selected from the group consisting of hydrogen, halo, methyl, ethyl, trideuteromethyl, trifluoromethyl, and cyclopropyl; and R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, tritium, and methyl. Pharmaceutical compositions including Formula I compounds and methods of treating cancer by administering Formula I compounds are also provided herein.
Methods and systems for delivery of pulsated air to a user using a device including a flow generator to generate a continuous air flow, a first actuator comprising a pulsated flow delivery mechanism configured to generate a pulsated air flow from the continuous air flow based on a pre-determined duty cycle to vary a frequency of the pulsated air flow, a user interface configured to generate and deliver vortices of pulsated air to the user at the frequency of the pulsated air flow, and a set of tubing to couple the flow generator, the first actuator, and the user interface.
The present invention involves a method of targeted imaging of a bacterial infection in a subject. In one embodiment, the method includes administering pyochelin (PcH) bound to a radiometal to the subject and imaging the infected area of the subject using a positron emission tomography-computed tomography (PET/CT) scan. In one embodiment, the pyochelin bound to a radiometal is selected from the group consisting of copper-64 bound pyochelin and gallium-68 bound pyochelin.
A method of treating cancer metastasis in a subject in need thereof is provided, the method including administering to the subject a combination therapy including: (a) a vascularization and/or tissue remodeling inhibitor; (b) a suppressor of oxidative metabolism; and (c) an ion homeostasis modulator. Pharmaceutical compositions directed to the combination of therapeutic agents are also provided.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A novel genetically modified bacterium is disclosed. The bacterium has one or more anti-spike glycoprotein nanobodies on the outer membrane of the bacterium. In one embodiment, one or more of the anti-spike glycoprotein nanobodies have been fused with Intimin. In another embodiment, one or more of the anti-spike glycoprotein nanobodies have been fused with Lpp-OmpA.
A method for performing an analysis related to potential rejection of an organ after transplantation in a subject is provided. The method involves identifying alloreactive/expanded CD8 T cell clones in either an allograft biopsy or a urine sample from the subject, wherein the T cell clones are identified using a single cell RNASeq (scRNAseq)/TCRseq test. In one embodiment, the analysis is selected from the group consisting of detection of rejection, diagnosis of rejection, treatment selection, therapeutic monitoring for rejection, identification of resistance to rejection treatment, and combinations thereof.
Systems and methods for delivering a drug to a patient's kidney. The present systems comprise a urethral catheter and a ureteral catheter sized to fit through the urethral catheter. The urethral catheter includes a balloon configured to be inflated in the patient's bladder to retain the urethral catheter in the patient's urethra. The ureteral catheter includes a balloon configured to be inflated in the patient's ureter and/or kidney while a distal end of the ureteral catheter is disposed in the patient's kidney. The ureteral catheter balloon can help retain liquid in the kidney to enable expanded contact areas with kidney tissues and extended dwell times (e.g., periods of exposure) of the drug in the kidney. The balloons also help retain the catheters in the patient's urinary tract, such that the catheter system can be used to deliver a drug to the patient's intermittently or periodically over a period of days or weeks.
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
34.
METHODS OF POTENTIATING TEMOZOLOMIDE ACTIVITY AGAINST GLIOBLASTOMA CELLS
Provided herein is a method of potentiating a cytotoxic effect of temozolomide against glioblastoma cells in a subject in need thereof, the method including administering to the subject a combination of: a therapeutically effective amount of temozolomide; and a non-cytotoxic amount of letrozole, wherein the letrozole potentiates the cytotoxic effect of the temozolomide against the glioblastoma cells. Also provided is a method of restoring sensitivity of temozolomide-resistant glioblastoma cells to temozolomide, including contacting the glioblastoma cells with a non-cytotoxic amount of letrozole and method of treating glioblastoma.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/175 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine having the group , N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazonesThioanalogues thereof
A device for measuring an analyte comprises a sensor including an electrode with an aptamer and an attached redox couple. The sensor is adapted to electrochemically measure a change in concentration of the analyte. The device further comprises a detection circuit configured to select a sampling frequency at which a measurement is taken. The detection circuit is further configured to periodically apply an input voltage to an electrode to obtain a measured response of the electrode. The measured response includes a target signal of the aptamer and an artifact. The detection circuit is further configured to detect the artifact using a transformative tool. The detection circuit is further configured to apply a filter to the measured response of the electrode to attenuate or remove the artifact. The detection circuit is further configured to measure the analyte using the target signal and not the artifact.
A method for continually sensing at least one analyte. The method includes bringing a sample including at least one analyte into contact with at least one sensor having an electrode and a plurality of aptamers that are capable of binding to the analyte. At least some of the aptamers each carry at least one tag (such as a redox tag), wherein each tag changes in at least one parameter when analyte binds to its associated aptamer (such as by being brought closer to or further from, on average, the electrode (which results in a measurable change in electrical current that can be translated to a measure of presence or concentration of the analyte). The method also includes applying a first electronic waveform to the at least one sensor, wherein the first electronic waveform is associated with a first binding affinity between the analyte and the plurality of aptamers. The method also includes applying a second electronic waveform to the at least one sensor, wherein the second electronic waveform is associated with a second binding affinity between the analyte and the plurality of aptamers. The first electronic waveform and second electronic waveform are different waveforms, and the first binding affinity and second binding affinity differ by at least 2X.
The present invention is directed to a method and apparatus for simultaneously implementing mechanochemical and electrochemical synthesis conditions. With respect to the method, the method may be configured to improve one or more reaction metric such as increasing product yield, reducing organic solvent consumption, reducing the reaction time, reducing the amount of, or completely eliminating, at least one toxic reagent or solvent, or enabling electrochemical synthesis of the chemical product without complete solubility of the organic substrate in the organic solvent. With respect to the apparatus, the apparatus is configured to define a reaction area between an anode and cathode that can be mechanochemically agitated to improve synthesis without disrupting the electrochemical reaction.
Provided herein are compositions including ionizable lipids and lipid nanoparticles comprising the ionizable lipids. The ionizable lipids may have a general structure according to formula I: (I). Lipid nanoparticles generally include the ionizable lipid according to formula (I); a helper lipid; a sterol; and a PEGylated lipid conjugate. The ionizable lipids and lipid nanoparticles may be used to carrier cargo for a vaccine.
C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
39.
Single Waveform, Continuous Squarewave Voltammetry for Optimal Calibration Free Sensing
A method of measuring sensor response for a sample is disclosed. The sample is exposed to an electrochemical aptamer-based (EAB) sensor, where the sensor includes an electrode and one or more aptamers having redox tags. Next, an interrogation is performed by applying an abrupt voltage pulse to the electrode. Two or more data samples are collected at different time values, where each data sample is a redox tag current value. Then at least one measure of the sample is identified using the data samples.
A complex of curcumin with a polyphenolic macrocyclic host is disclosed. The macrocyclic host is a resorcin[4] arene. In one approach, the polyphenolic macrocyclic host is calix[8] arene. In another approach, the polyphenolic macrocyclic host is tert-butylcalix[8] arene.
Methods of treating lung cancer in a subject in need thereof are provided, including administering to the subject an effective amount of an imidazolate gold compound according to Formula I, or a pharmaceutically acceptable salt, racemate, or enantiomer thereof:
Methods of treating lung cancer in a subject in need thereof are provided, including administering to the subject an effective amount of an imidazolate gold compound according to Formula I, or a pharmaceutically acceptable salt, racemate, or enantiomer thereof:
Methods of treating lung cancer in a subject in need thereof are provided, including administering to the subject an effective amount of an imidazolate gold compound according to Formula I, or a pharmaceutically acceptable salt, racemate, or enantiomer thereof:
wherein R1 and R2 are independently selected from the group consisting of halo, cyano, hydroxyl, carboxyl, alkyl, aryl, esteryl, amidyl, and alkoxyl. Methods of inducing ferroptosis in a lung cancer cell and pharmaceutical compositions are also provided.
A method of determining platelet aggregation forces is provided. The method involves embedding tension sensor-coated microbeads in platelet clots and observing fluorescent signals from the microbeads that correspond to contractile forces exerted on the tension sensor-coated microbeads to report platelet aggregation forces. In one embodiment, the platelet aggregation forces are used as biomechanical markers to evaluate platelet functions. In another embodiment, the fluorescent signals can be read directly by a plate reader.
G01N 11/14 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties by moving a body within the material by using rotary bodies, e.g. vane
G01N 33/86 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood coagulating time
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
44.
Lift-Based Peel Separation for Inverted Vat Photopolymerization 3D Printing
A method of inverted SLA 3D printing with a printing device is disclosed. The method involves a) lifting a thin elastic membrane to an elevated position within a resin filled vat via vertical movement of an optical module, the resin filled vat, or both. b) allowing resin on the thin elastic membrane to cure as a current layer, the layer being attached to a printed part, and c) peeling the thin elastic membrane from the current layer by lowering the optical module, raising the resin filled vat, or both.
B29C 64/124 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
A device and method for detecting the presence of, or measuring the concentration or amount of, at least one large analyte in a sample fluid. The device has at least one electrode, a sample fluid and a plurality of aptamers capable of binding to the analyte. The aptamers are physically bound to the device. In addition, the aptamers each include at least one redox tag and also, the aptamers have two or more binding portions that bind to two or more distinct binding sites on the analyte in the sample fluid.
Certain aspects of the disclosure provide systems and methods for generating predictions of mood disorder. For example, one method may include presenting a set of stimuli and receiving a set of ratings for the set of stimuli from a subject. The method further includes determining a set of judgment variables based on the set of ratings. The method further incudes generating a mood disorder prediction based on the set of judgment variables and treating the subject based on the mood disorder prediction.
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data
G16H 40/00 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
H01M 12/06 - Hybrid cellsManufacture thereof composed of a half-cell of the fuel-cell type and of a half-cell of the primary-cell type with one metallic and one gaseous electrode
A method to prevent calcification of an injury site in a subject is provided. The method involves injecting the injury site with a composition including a hydrogel and the hydrogel comprises poly(aspartic acid) (PASA). In one embodiment, the hydrogel is formed by combining thiol- functionalized PASA with one or more maleimide-functionalized crosslinkers. Additionally, a method to prevent premature bone fusion in a pediatric subject's skull is provided. The method involves injecting one or more cranial sutures of the skull with a composition including a hydrogel and the hydrogel comprises poly(aspartic acid) (PASA).
C08J 3/09 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in organic liquids
C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
C08L 29/02 - Homopolymers or copolymers of unsaturated alcohols
49.
Electrochemical Aptamer Sensors with Signal Amplification Via Multiple Redox Tags
A device for detecting the presence of, or measuring the concentration or amount of, at least one analyte in a sample fluid is disclosed. The device includes at least one electrode; a sample fluid; and a plurality of affinity-based probes capable of binding to the analyte, wherein the affinity-based probes each carry a plurality of redox tags. Further, the detection or measurement of an analyte is caused by analyte binding to the affinity-based probe which further causes a change in electron transfer from the redox tags.
A device for modeling a brain tumor microenvironment and testing therapeutic efficacy is provided. The device includes a vascular tissue model and an ultrasound device that is capable of delivering focused ultrasound insonation. The vascular tissue model includes a rigid 3D printed scaffold. The scaffold includes one or more scaffold microfluidic channels, two or more inlets, and a central chamber. The central chamber contains a hydrogel or other biocompatible scaffolds. The hydrogel includes one or more hydrogel microfluidic channels as well as living cells.
Certain aspects of the disclosure provide systems and methods for diagnosing and treating chronic liver disease and portal vein thrombosis. In particular, methods may include measuring levels of one or more proteins, including factor V, factor VIII, protein C, protein S, D-dimer, sP-selectin, or asTF in a biological sample from a subject and determining a CLD score based on the levels of the one or more proteins, whereby, a CLD stage may be determined based on the CLD score. In some aspects, methods may include determining a PVT score based on levels of the one or more proteins in the biological sample. In some aspects, methods further include treating CLD and/or PVT.
A novel endonasal method for occipitocervical fusion is provided. This new method provides a minimally invasive advance in the ability of surgeons to treat pathology of the craniocervical junction. The method uses an implant system comprising a body having a spacer section that engages with the occipital condyle and a plate section that engages with the C1 lateral mass. Fasteners fix the plate section with the occipital condyle the plate section with the C1 lateral mass.
A device for detecting or measuring at least one large analyte in a sample fluid. The device includes at least one electrode; a sample fluid; and a plurality of aptamers capable of binding to the analyte, wherein the aptamers are physically bound to the device. A majority of the aptamers comprise a first molecule and a second molecule. The first molecule is a redox tag or redox molecule. The second molecule, when it is brought into proximity of the first molecule, results in decreased redox electron transfer with an electrode at a given voltage.
Provided herein is a device for rapid fixation and embedding of a biological specimen, the device including a barrel having a first end and a second end, the first end receiving a plunger and the second end opening to a compartment defining a block mold; and a plunger for inserting in the barrel, the plunger having a first end, a second end, and an interior conduit connecting the first and second ends, wherein the first end of the plunger connects to a vacuum source and the second end of the plunger includes a filter barrier between the interior conduit of the plunger and a receptacle for receiving, fixing, and embedding the specimen, the receptacle defined inside the barrel when the plunger is disposed in the barrel. Also provided are a system and method for rapid fixation and embedding of a biological specimen.
A novel method for treating hyponatremia or polycystic kidney disease in a mammal is disclosed. The method involves administering to the mammal in need of such treatment a therapeutically effective amount of an adenine analog selected from the group consisting of: 2-chloro-6-aminopurine, its tautomer, racemate, optical isomer and/or pharmaceutically or nutritionally acceptable salt thereof, and a pharmaceutical carrier, 6-(dimethylamino) purine, its tautomer, racemate, optical isomer and/or pharmaceutically or nutritionally acceptable salt thereof, and a pharmaceutical carrier; and combinations thereof.
A continuous sensing device configured for sensing both oxygen and at least one other analyte in a fluid in a single measurement scan comprising a first electrode. A method of measuring both oxygen concentration and the concentration of at least one other analyte using sensing device comprising a first electrode. The method comprises measuring current in a first potential zone, wherein that current correlates to concentration of the at least one other analyte, and measuring current in a second potential zone, wherein that current correlates to a concentration of oxygen. The method may further comprise configuring the first electrode to measure a greatest measured current over baseline to a maximum within one or both of the two potential zones for a duration.
Systems, methods, and computer program products for minting non-fungible tokens (52). The system includes a computing device (18, 24) that receives a dynamic uniform resource identifier (URI) (64) including a unique identifier and a hostname that identifies a host system (12). In response to receiving the dynamic URI (64), the computing device (18, 24) transmits data to the host system (12) identified by the hostname. The data includes the unique identifier and at least one of a time the computing device (18, 24) received the URI (64) and a physical location of the computing device (18, 24) when the URI (64) was received. In response to receiving the data from the computing device (18, 24), the host system (12) mints a non-fungible token (52) on a blockchain (30) that documents at least one of the time the computing device (18, 24) received the URI (64) and the physical location of the computing device (18, 24) when the URI (64) was received.
G06F 21/73 - Protecting specific internal or peripheral components, in which the protection of a component leads to protection of the entire computer to assure secure computing or processing of information by creating or determining hardware identification, e.g. serial numbers
G06F 21/33 - User authentication using certificates
In one aspect of the present invention, a genetically modified Anti-Mullerian Hormone (AMH) is disclosed where one or more cysteine residues in the prodomain are replaced with amino acid residues other than cysteine. In one embodiment, one or more cysteine residues in the prodomain are replaced with serine residues. In one embodiment, cysteine 241 of the prodomain is replaced with a serine residue.
METHODS FOR SELF-SEEDED HYDROTHERMAL GROWTH OF MFI ZEOLITE NANOSHEETS AND NANOSHEET ASSEMBLIES AND FOR TILING NANOSHEET ZEOLITE PLATES ON POLYMER SUPPORTS
The present invention relates to methods for synthesizing MFI zeolite nanosheet (ZN) assemblies and open-pore ZN plates and for tiling ZN plates on polymer supports. Methods for producing ZN assemblies and ZN plates may reduce or eliminate the need to synthesize nanoparticle (NP) seed-evolved single-crystal zeolite nanosheets (ZNs) as an intermediate product. Methods for tiling ZN plates on polymer supports may produce ZN plate-tiled (ZNPT) membranes with reduced permeation through intercrystalline spaces.
B01J 20/10 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B01J 20/30 - Processes for preparing, regenerating or reactivating
C30B 7/14 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
A method of making a polyurethane polymerized high internal phase emulsion (polyHIPE) is disclosed. The method involves preparing a polyurethane prepolymer and crosslinking the polyurethane prepolymer using a thiol-alkene Michael addition, producing a polyurethane polymerized high internal phase emulsion. In one embodiment, the polyurethane prepolymer is prepared by reacting diisocyanate and trimethylolpropaneallylether (TMPAE).
C08G 18/67 - Unsaturated compounds having active hydrogen
C08G 18/73 - Polyisocyanates or polyisothiocyanates acyclic
C08G 18/75 - Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic
C08G 18/76 - Polyisocyanates or polyisothiocyanates cyclic aromatic
C08G 18/87 - Chemically modified polymers by sulfur
C08J 9/28 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
61.
SYSTEMS AND METHODS FOR AERIAL VEHICLES EQUIPPED WITH CONTROL MOMENT GYROSCOPES
An aerial vehicle system includes one or more actuators; a processor; and a non-transitory, computer-readable storage medium communicatively coupled to the processor. The processor is configured to: receive one or more predetermined state values, wherein the one or more predetermined state values include one or more user values associated with aerial instability including turbulence, motion sickness, or any combination thereof; receive one or more sensing parameters; compare the one or more predetermined state values with the one or more sensing parameters; generate, based on the comparison, one or more signals to stabilize an aerial vehicle; transmit the one or more signals to the one or more actuators; and control, in response to the one or more signals, stabilization of the aerial vehicle by the one or more actuators.
B64C 13/16 - Initiating means actuated automatically, e.g. responsive to gust detectors
B64C 27/82 - RotorcraftRotors peculiar thereto characterised by the provision of an auxiliary rotor or fluid-jet device for counter-balancing lifting-rotor torque or changing direction of rotorcraft
G01S 17/50 - Systems of measurement based on relative movement of target
A method of making sensors with a plurality of aptamers and performing continuous measurements with the sensors is provided. The method involves fabricating a plurality of sensors where each sensor has at least one electrode with a plurality of aptamers attached to the electrode surface. A portion of the plurality of sensors is calibrated and a portion of the plurality of aptamer sensors is identified as being commercial quality ("the product portion"). At least one set of calibration data gathered from the calibration of the plurality of sensors is associated mathematically to the product portion.
A61B 5/1495 - Calibrating or testing in vivo probes
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
Supramolecular inclusion complexes comprising sulfonato methylresorcinarenes according to Formula I and a fluoroquinolone compound are provided. Also provided are pharmaceutical compositions comprising the supramolecular complexes and methods of using the supramolecular complexes to treat bacterial infections, kill or inhibit growth of bacteria, and disrupt bacterial biofilms.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
64.
INDUSTRIAL HEAT PUMPS FOR TRANSPORTING HEAT WITH A REFRIGERANT AND A METHOD OF OPERATING THE SAME
An industrial heat pump includes an evaporator configured to transfer heat into a refrigerant, a condenser configured to transfer the heat out of the refrigerant to a heat sink, a first fluid path, a second fluid path, and an expansion valve defining a portion of the first fluid path. The industrial heat pump includes a thermal storage unit defining a portion of the second fluid path. The thermal storage unit is configured to receive and store heat from the refrigerant in the second fluid path. The industrial heat pump includes a compressor defining a portion of the second fluid path between the thermal storage unit and the condenser. The heat received by the thermal storage unit causes a portion of the refrigerant to phase change from a gas to a liquid allowing for wet compression of the refrigerant through the compressor where the refrigerant phase changes to a gas.
Described are sensing devices and methods that continuously sense an analyte included in an interstitial fluid. The device includes at least one ex-vivo sensor specific to the a least one analyte in interstitial fluid. The device further includes at least one sample collection component in the dermis that defines at least in part an advective pathway to transport interstitial fluid to the at least one sensor. The advective pathway is air-tight, and at least one integrated pump applies negative pressure to cause advective transport of interstitial fluid from the dermis, to the sensor, and onto the pump.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 5/1477 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means non-invasive
A three-dimensional microfluidic device is provided. The device includes an array of fluid transporting channels formed in a permeable gel. The channels allow both direct circulation flow and diffusion flow from a channel into the gel. The diffusion flow is lateral to the direction of the channel. The device also includes one or more fluid movement devices capable of controlling the circulation flow to enable control of flow pattern in the permeable gel. The device further includes one or more types of organoids cultured in the device.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
UNIVERSITY OF CINCINNATI (USA)
Inventor
Deng, Zicheng
Kalinichenko, Vladimir
Shi, Donglu
Abstract
Polymers based on a poly(β-amino) ester (PBAE) backbone are provided, with improved targeting of the lung endothelium following parenteral delivery. The disclosed polymers are polymers of a primary amine (A2), a secondary amine (A1), a diacrylate (D) and at least one end-capping hydrophilic compound (C) such as amine. The polymer is halogenated (hereinafter, halogenated PBAE polymer), preferably, fluorinated. The hydrophobic PBAE backbone is end capped with a hydrophilic compound by covalent attachment of these capping agents to the PBAE backbones via Michael Addition to form a halogenated PBAE. The disclosed polymers can be used to encapsulate/incorporate an active agent for targeted delivery to lung endothelial cells.
A nozzle (30) for a jet engine (32) is disclosed. The nozzle (30) includes at least one sweeping jet actuator (10) operatively coupled to the nozzle (30). The sweeping jet actuator (10) has an inlet opening (14) and a discharge slot (26). The inlet opening (14) is configured to receive a supply of air (40) and the discharge slot (26) is configured to discharge that supply of air in a sweeping motion (42) into and interacting with an air flow (36) moving through the nozzle (30). A jet engine (32) with a nozzle (30) and a sweeping jet actuator (10) coupled to the nozzle (30) is also disclosed. A method of operating a jet engine (32) having a nozzle (30) with a sweeping jet actuator (10) is further disclosed.
F02K 1/34 - Plants characterised by the form or arrangement of the jet pipe or nozzleJet pipes or nozzles peculiar thereto using fluid jets to influence the jet flow for attenuating noise
Methods, systems, and computer program products for providing an educational environment using agentic artificial intelligence. A prompt is received from a system user (220), and a response to the prompt is generated using a large language model (208). The response includes raw content defining a clinical scenario consistent with the prompt. The raw content is interpreted using fuzzy logic (213) to generate filtered content based on the first raw content, and the filtered content is displayed to the user (220). In response to the user (220) inputting additional prompts responsive to the filtered content, the large language model (208) generates another response including raw content that defines an updated clinical scenario consistent with both the initial clinical scenario and the additional prompts received from the user. The fuzzy logic (213) generates new filtered content based on the new raw content, and this filtered content is displayed to the system user (220).
The present invention relates to a catalyst for degrading perfluorooctanoic acid (PFOA) in solution, comprising bimetallic catalytic nanoparticles immobilized on a substrate. The nanoparticles may include metals such as iron, manganese, cobalt, nickel, copper, and titanium. The substrate may be an ion exchange resin, such as an anion exchange resin. Methods for synthesizing the catalyst may include dissolving metal salts in water, titrating with a reducing agent, and immobilizing the nanoparticles on the resin. Methods of degrading PFOA include providing a plurality of bimetallic catalytic nanoparticles to a first solution comprising perfluorooctanoic acid. The method may optionally include additional steps for immobilizing the bimetallic catalytic nanoparticles, synthesizing the bimetallic catalytic nanoparticles, purging the first solution with an inert gas, and/or adjusting the pH of the first solution.
A stent for a bladder is provided. The bladder includes a drainage tube, a shell with flexible leaf-shaped sections ("spring leaves") and a string tether. The shell surrounds the drainage tube and the tether is attached to the drainage tube. In addition, the spring leaves are attached at the top of the drainage tube and the spring leaves are attached at the bottom of the shell by a ring with an opening through which the drainage tube can pass freely.
Myopeptides are provided, which include a myosin S2 fragment having at least 90% sequence identity to an amino acid sequence consisting of VKEMTERLEDEEEMNAELTAKK (SEQ ID NO: 1); and, optionally, a cardiac-homing peptide tag. Also provided are pharmaceutical compositions and methods of use of the myopeptides and pharmaceutical compositions in the treatment of heart failure.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 9/00 - Medicinal preparations characterised by special physical form
A method of incorporating one or more linkers into a biomaterial with one or more ketone units is disclosed. The method involves reacting a linker-containing material selected from the group consisting of thiol-containing compositions, thioketal-containing compositions, selenol-terminated compositions and combinations thereof with the biomaterial in the presence of an acid catalyst.
The present invention relates to a device for continuous sensing of at least one analyte in a test fluid that is resistant at least one of desorption of a first plurality of molecules, including a plurality of aptamers and a blocking layer, and fouling during use of the device when exposed to temperatures greater than or equal to 30° C. for at least 3 days. Another aspect of the invention is a method of providing fouling resistance to an aptamer sensor device wherein the blocking layer and aptamer are resistant to at least one of desorption from the electrode and fouling during use of the aptamer sensor when exposed to temperatures greater than or equal to 30° C. for at least 3 days.
The present disclosure concerns fluorescent probes of pyridine, quinolinium and piperazine covalently linked as a small molecule probe. The probes can be administered to cells and are readily uptaken thereby. The probes locate particularly into endolysosomes. The probes provide two types of fluorescence with pH-sensitive photophysical properties, which in turn allows for the observation and analysis of changes occurring during varying stages of interest. The dual fluorescence provides for simultaneous monitoring of two fluorescence signals in endolysosomes at different stages of interest and minimizes the interference from various microenvironments.
C07D 215/02 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 213/02 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
C07D 215/12 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using chemical indicators
76.
Shelf-Stable Sterilization of Aptamer-Sensors for In-Vivo Measurement in Humans
A method of measuring analytes in a subject in vivo for a period of time is provided. The method involves storing a device. The device includes at least one sensor comprising an aptamer material; at least one feature for coupling said sensor to an analyte in the subject in vivo; at least one sterilization state that imparts sterilization on at least one component of the device; at least one sterile packaging material enabling a storage state; and at least one aptamer storage material. The sensor is contained in the sterile packaging material and the storage material is anhydrous. Further, wherein the sensor and the feature are sterile. The method further involves removing the sterile packaging material from the device and using the feature to couple the sensor to an analyte in the subject.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
77.
ELECTROCHEMICAL APTAMER SENSOR MONOLAYER INCUBATION WITH IMPROVED STABILITY
A method of fabricating an electrochemical aptamer sensor is provided. The method includes incubating an electrode including a sensing monolayer. The sensing monolayer includes at least a plurality of aptamers and at least one weakly bonded constituent. The method further includes removing the at least one weakly bonded constituent from the sensing monolayer by applying at least one perturbation mechanism to the sensing monolayer while incubating the electrode.
An electrocatalyst ink composition is provided. The ink composition includes a liquid vehicle, particles with at least one electrocatalyst metal, and at least one compound having a phenolic moiety. In various embodiments, the compound comprising a phenolic moiety is resorcinol and the electrocatalyst metal is a platinum-bismuth alloy.
A device for detecting or measuring at least one large analyte in a sample fluid is provided. The device includes at least one substrate and a plurality of multi-bond aptamers capable of binding to the analyte. The aptamers are physically bound to the substrate and include at least one tag capable of providing a signal. Also, the multi-bond aptamer has a change in geometry when the multi-bond aptamer binds to the analyte. Further, the tag has a resulting change in signal resulting from the analyte binding to the multi-bond aptamer and associated change in geometry.
An apparatus may comprise a controller programmed to establish a connection with an integrated circuit, program a plurality of cross-coupled look up tables of the integrated circuit to generate a plurality of memory cells, each pair of cross-coupled look up tables comprising one memory cell, and associate a plurality of the memory cells with a digital fingerprint of the integrated circuit, a value of each memory cell after startup of the integrated circuit comprising one bit of the digital fingerprint.
G06F 21/73 - Protecting specific internal or peripheral components, in which the protection of a component leads to protection of the entire computer to assure secure computing or processing of information by creating or determining hardware identification, e.g. serial numbers
G06F 30/34 - Circuit design for reconfigurable circuits, e.g. field programmable gate arrays [FPGA] or programmable logic devices [PLD]
H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
22 separation is provided. The sorbent chemical includes an amine functionalized with an epoxide chemical impregnated onto a mesoporous silica support. The amine is selected from the group consisting of polyethylenimine, tetraethylenepentamine, and pentaethylenehexamine. Also, the epoxide chemical is selected from the group consisting of isobutylene oxide (TBO), dimethyl- 1,2-epoxybutane (DMEB), epoxy octane (EO), styrene oxide (SO), phenyl glycidyl ether (PGE), glycidyl 4-methoxyphenyl ether (GMPE), butyl glycidyl ether (BGE), glycidyl isopropyl ether (GIPE), 2- (tert-butoxymethyl oxirane) (TBGE), and neopentyl glycol diglycidyl (NGD).
B01J 20/10 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
C08G 59/18 - Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups
A method of treating pancreatic adenocarcinoma in an individual is disclosed. The method involves administering to the individual a therapeutically effective amount of a therapeutic agent comprising recombinant acid sphingomyelinase. In one embodiment, the therapeutic agent further includes one or more compositions selected from the group consisting of modified enzymes, fusion proteins and constitutively active mutants. In another embodiment, the therapeutic agent further includes a pharmaceutically acceptable excipient.
A61P 35/04 - Antineoplastic agents specific for metastasis
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
Disclosed herein are compositions and methods for treating an individual having a leukemia. In certain aspects, the methods may include administering an I0DVA1 compound and ponatinib to an individual in need thereof for treatment of a leukemia, which may include, for example, TKI-resistant leukemia, TKI-resistant Ph+ B-ALL, Chronic Myelogenous Leukemia (CML), Ph-Positive Acute Lymphoblastic Leukemia (ALL), Ph-like ALL, Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML), MLL-rearranged B-ALL, and VAV3 positive leukemia.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61P 35/02 - Antineoplastic agents specific for leukemia
84.
SYSTEMS AND METHODS FOR PREDICTING AIRPORT PASSENGER FLOW
A computing device includes a controller to receive passenger data based on airport scans of boarding passes, determine time until takeoff data for passengers, determine passenger flow histograms based on the time until takeoff data, transform the passenger flow histograms into continuous passenger flow profile curves, determine input similarity matrices between a first flight and past flights having scheduled departures on the same day of the week based on input similarity scores, determine output similarity matrices between the first flight and the past flights based on passenger flow profile curves associated with the first flight and the past flights, determine past flights that are most similar to the first flight based on the input similarity matrices and the output similarity matrices, and determine a predicted passenger flow profile curve for the first flight based on the passenger flow profile curves associated with the most similar past flights.
G06Q 10/04 - Forecasting or optimisation specially adapted for administrative or management purposes, e.g. linear programming or "cutting stock problem"
G06Q 10/02 - Reservations, e.g. for tickets, services or events
G06Q 50/40 - Business processes related to the transportation industry
A biphasic membrane-free battery and a triphasic membrane-free battery are provided. The biphasic membrane-free battery includes a housing structure housing: a catholyte phase having a cathode, and an anolyte phase having an anode, the catholyte phase contacting the anolyte phase along an interface. The triphasic membrane-free battery includes a housing structure housing: a catholyte phase having a cathode, and an anolyte phase having an anode, and an electrolyte phase between the catholyte phase and the anolyte phase.
A novel method of making a 3D-shaped 3D graphene (3D2G) is disclosed. The method involves a) 3D printing a catalyst slurry via Direct Ink Writing (DIW); b) depositing the printed slurry using chemical vapor deposition (CVD) to produce a nickel-graphene composite; and c) etching the nickel-graphene composite. The resulting composite is a porous, binder-free structure of pure 3D2G. In one embodiment, the catalyst slurry comprises nickel particles mixed with an organic solvent, a polymer, and a plasticizer. In another embodiment, the organic solvent is dichloromethane, the polymer is poly lactic-co-glycolic acid and the plasticizer is dibutyl phthalate.
A device for continually sensing at least one analyte in a sample fluid via measurement of the analyte is provided. The device includes at least one sensor with surface having a plurality of aptamers that bind to the analyte. The aptamers carry at least one tag that changes in at least one electrical parameter as analyte binds to the aptamers. The surface also has a protective layer that protects the surface from fouling in between the aptamers. The protective layer includes a monolayer of molecules that form a boundary with the sample fluid and the monolayer is a mixed conductivity monolayer.
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
88.
ELECTROCHEMICAL APTAMER SENSORS WITH APTAMERS BOUND ADJACENT TO THE ELECTRODE
An aptamer sensing device is provided. The aptamer sensing device 200 includes at least one electrode 220. The aptamer sensing device further includes at least one binding feature 230. The aptamer sensing device further includes a plurality of aptamers 270 attached to the binding feature and not individually attached to the electrode, the aptamers further having an attached redox couple 272. The aptamer sensing device is configured to accept a sample fluid 242 including at least one analyte, and the binding feature is positioned relative to the electrode such that a binding of the analyte to the aptamers causes a shape change configuration in the binding feature that increases or decreases a charge transfer from the redox couple to the electrode.
A composition including ionizable lipids is provided. Also provided is a composition forming lipid nanoparticle, wherein the composition includes the ionizable lipid, a helper lipid, a sterol, and a PEGylated lipid conjugate. Also provided are methods of making the ionizable lipids. The ionizable lipids can include 2AEOAP2, 2AEOAP4, 2AELAP2, 2AELAP4, Lipid 16A, Lipid 16B, Lipid 16C, Lipid 16B, and Lipid 20B.
C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A device for continually sensing at least one analyte in a sample fluid via measurement of the analyte is provided. The device includes an optically transparent component adapted for in-vivo placement. The device also includes a plurality of aptamers bound to the optically transparent component. The aptamers are capable of binding to the analyte. Also, the aptamers carry at least one tag that changes in at least one optically measurable property when the aptamers bind to the analyte. Additionally, an optical source and detector coupled to the optically transparent component can measure the optically measurable property of the aptamers.
A device for continually sensing at least one analyte in a sample fluid via measurement of the analyte is provided. The device has a sensor with a surface having a plurality of aptamers that bind to the analyte. The plurality of aptamers carries at least one tag. The surface also has a protective layer that protects the surface from fouling in between the aptamers. The protective layer has a monolayer of molecules that form a boundary with the sample fluid. Further, the monolayer of molecules is a mixed charge monolayer.
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
Certain aspects described herein include systems and methods for predicting vaccine uptake. A method includes presenting, to a user via a user interface, a set of stimuli; and receiving, from the user via the user interface, a set of ratings associated with the set of stimuli, wherein each respective rating in the set of ratings corresponds with a respective stimuli in the set of stimuli. The method further includes determining a set of judgment variables based on the set of ratings; and generating, with a machine learning model, a vaccine uptake prediction based on the set of judgment variables, wherein the machine learning model is trained to determine a vaccination status of users.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
93.
BIOSENSOR FOR PLACEMENT AT SKIN DEPTHS THAT ARE NOT PREDETERMINED
A wearable device for continuous monitoring of at least one analyte is provided. The device includes a plurality of aptamer sensors for a specific analyte and a means to determine at least one location measurement. The sensors are capable of being placed in a distinct location with respect to depth into a user's skin. The location measurement has a distinct measurement response between at least two skin tissues such as epidermis, dermis, and hypodermis. Also, at least one of the sensors is capable of being placed at a distinct tissue location.
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
Provided herein are methods of potentiating an effect of an anti-cancer drug in a subject diagnosed with cancer, the method including administering to the subject a combination therapy including: an effective amount of 7-ethynyl-5-(2-fluorophenyl)-1-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (BZD-1); and an anti-cancer drug.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A rotating detonation combustor includes a nozzle coupled to the combustor body at or near the exhaust opening to choke the exhaust opening. A rotating detonation combustor may include a diverting plate positioned radially inward of the inlet annulus and inlet channels for diverting flow of a mixture in an axial direction. A rotating detonation combustor may include a combustor body including an outer shell at least partially defining a detonation combustion chamber and extending axially from a base toward an exhaust opening of the detonation combustion chamber. The base defines a passageway in fluid communication with the detonation combustion chamber and includes an inlet annulus for axially directing a second fluid into the passageway and a plurality of inlet channels for radially directing a third fluid into at least one of the passageway or the detonation combustion chamber, and the detonation combustion chamber is free of any inner body.
A probe for positron emission tomography (PET) is disclosed. The probe is selected from the group consisting of yersini-abactin (Ybt) labeled with Copper-64; staphylopine (StP) labeled with Copper-64; yersiniabactin (Ybt) labeled with Zirconium-89; and staphylopine (StP) labeled with Zirconium-89.
22+22+2242+2252+2+ product when the one or more single-site dopants has an oxophilicity that is less than the oxophilicity of Cu or greater than the oxophilicity of Ru.
C25B 11/091 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds
A method of determining an initial concentration of an analyte in a sample fluid is provided. The method includes providing a plurality of irreversible probes (182b), the plurality of irreversible probes (182b) each including at least one binding site configured to bind to an analyte (180). The method further includes introducing a sample fluid (140b) to the irreversible probes (182b) allowing binding of the analyte (180) to the irreversible probes (182b) at the binding site, the analyte 180 binding to the at least one of the plurality of irreversible probes (182b) produces a change in a signal having a signal strength. After the signal strength is unchanged for a period of time, the method includes calculating the initial concentration of the analyte in the sample fluid based on the signal strength.
377, and a basic anolyte with an aldehyde therein. The aldehyde reacts with the hydroxyl groups from the catholyte to produce hydrogen and the catholyte reacts water therein with the electrons from the anolyte to also produce hydrogen in a highly Faradaic efficient system. Application of the present disclosure not only provides for production of clean hydrogen, but also offers an approach for aldehyde decontamination.
In one embodiment, a combustor (50) includes a nozzle (52) coupled to the combustor body (12) at or near the exhaust opening (26) to choke the exhaust opening (26). In another embodiment, a combustor includes a diverting plate (74) positioned radially inward of the inlet annulus (40) and inlet channels (42) for diverting flow of a mixture in an axial direction. In another embodiment, a combustor (100) includes a combustor body (102) including an outer shell (104) at least partially defining a combustion chamber (108) and extending axially from a hollow base (106) toward an exhaust opening (112) of the combustion chamber (108). The hollow base (106) defines a passageway (126) in fluid communication with the combustion chamber (108) and includes an inlet annulus (142) for axially directing a first fluid (01) into the passageway (126) and a plurality of inlet channels (140) for radially directing a second fluid (F) into at least one of the passageway (126) or the combustion chamber (108), and the combustion chamber (108) is free of any inner body (20).
F23R 7/00 - Intermittent or explosive combustion chambers
F02C 3/14 - Gas-turbine plants characterised by the use of combustion products as the working fluid characterised by the arrangement of the combustion chamber in the plant
F02C 5/00 - Gas-turbine plants characterised by the working fluid being generated by intermittent combustion
